Invasive Fungal Infections after CD19 CAR T-cell Therapy for B-Cell Lymphoma: a LYSA study from the DESCAR-T Registry [0.03%]
CD19 CAR T细胞治疗B细胞淋巴瘤后侵袭性真菌感染：DESCAR-T登记册的LYSA研究
Amélie Bouvier,Amandine Durand,Vivien Dupont et al.
Amélie Bouvier et al.
Objective: To describe the landscape of IFI after chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies from the French national DESCAR-T registry and evaluate risk factors associated with invasive fungal...
Efficacy and safety of tedizolid in the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis of randomised controlled trials [0.03%]
特地唑烷治疗急性细菌性皮肤和皮肤结构感染的有效性和安全性：随机对照试验的系统评价和Meta分析
P Sevilla,A Martínez,O Pérez-Olaso et al.
P Sevilla et al.
Background: Acute bacterial skin and skin-structure infections (ABSSSIs) are usually caused by Gram-positive pathogens, particularly Staphylococcus aureus. Tedizolid, which belongs to the oxazolidinone family, has been pr...
Jesús Rodríguez-Baño
Jesús Rodríguez-Baño
Effectiveness of influenza vaccination to prevent severe disease: a systematic review and meta-analysis of test-negative design studies [0.03%]
预防流感重症的有效性：检验阴性设计研究的系统评价和meta分析
Sergey Yegorov,Om D Patel,Harsh Sharma et al.
Sergey Yegorov et al.
Background: Seasonal influenza vaccination may be effective against severe influenza disease. Objectives: To assess evidence on the rea...
Immune reconstitution in very advanced HIV patients treated with Dolutegravir vs Darunavir-based triple antiretroviral therapy. The Advanz-4 randomized clinical trial [0.03%]
多替拉韦与达芦那韦为基础的三联抗逆转录病毒疗法治疗终末期HIV感染者免疫重建的随机临床试验Advanz-4研究
Jose M Miro,Ferran Torres,Christian Manzardo et al.
Jose M Miro et al.
Objectives: The aim of this trial was to compare the immune reconstitution, virologic response, and safety of dolutegravir (DTG)- vs. darunavir (DRV) boosted-based antiretroviral (ART) regimens in very advanced HIV patien...
Enhancing SARS-CoV-2 Response Capacity in Africa and Other CREID Centers through a Collaborative Training Program [0.03%]
通过协作培训计划提升非洲及其他CREID中心对SARS-CoV-2的应对能力
Ambroise Ahouidi,Abdou Padane,Alioune Gaye et al.
Ambroise Ahouidi et al.
An open call to join the CMI editorial team: editor in infectious diseases [0.03%]
《CMI杂志感染病学编辑公开招聘》
Leonard Leibovici
Leonard Leibovici
Which trial do we need? Combination regimen for individuals exposed to multi-drug resistant Mycobacterium tuberculosis [0.03%]
我们需要哪一种试验？针对多药耐药结核病接触者的联合疗法试验
Divya Shah,Giovanni Fumagalli,Niccolo Riccardi et al.
Divya Shah et al.
Can we rely on using penicillin as the first-line treatment of pneumonia in outpatient care? [0.03%]
门诊治疗肺炎时能依赖青霉素吗？
Carl Llor,Niels Frimodt-Møller
Carl Llor
Corrigendum to Candidate anti-tuberculosis medicines and regimens under clinical evaluation [0.03%]
有关抗结核病药品和 regimen 的临床评价候选药物的更正通知书
Michael Hoelscher,David Barros-Aguirre,Masoud Dara et al.
Michael Hoelscher et al.